Funding Boosts AI for 3D Protein and RNA Mapping
Funding will support the development of advanced AI methods to map proteins and RNA structures in three dimensions. https://t.co/L6ZSpg8iMW #infrastructure #IoT #AI #5G #cloud #edge #futureofwork @virginia_tech https://t.co/7K7X1E9NpH
JRT: LSD-Derived Antidepressant Boosts Brain Spines without Hallucinations
One dose: > 46% more dendritic spines in prefrontal cortex > 100x more potent than ketamine as an antidepressant What is it? LSD with a two atom swap. > no trip > no hallucinations > no schizophrenia signature It's called JRT. https://t.co/sozMqlJctc
Balaji Predicts Booming Market for Bro Biotech
.@theojaffee asks Balajis for his thoughts on Clavicular, Balajis says he’s cheering for Clavicular because he’s tapping into bro biotech/bro science and that’s set to be a major market. Peptides, etc https://t.co/CgSt6rg1zI
CRISPR Advances Outpace Ethics in Germline Editing Debate
In 2018, He Jiankui edited the genomes of two human embryos, brought them to term, and went to prison for it. The babies are now children. We don't know how they're doing. Seven years later, base editing and prime editing can...
LLY's Second in Vivo CAR‑T Deal via Kelonia Buyout
Kelonia turns #ASH25 late-breaker into buyout, with $LLY's second move into in vivo Car-T. Via @ApexOnco -> https://t.co/NPhdnuhPu3 $AZN $GILD
Key Overlooked Factors in Clinical Trial Design
New presentation on things we often forget to consider when designing a clinical trial: https://t.co/BVlSCIHdLu #Statistics #clinicaltrials
Inside the $3.25B Eli Lilly Acquisition: Memo and Deck
Read the memo and slide deck that led to th creation of the company Eli Lilly bought for $3.25 billion today https://t.co/cNoTs7M4YM
Nektar Jumps as Alopecia Drug Shows Promise
Nektar surges again as alopecia drug shows new promise in extension study https://t.co/UV0ccY4HiR @ByJonGardner $NKTR + 25% $LLY
2018 Study Predicts Psilocybin Should Move to Schedule 4
The psychedelic executive order requires government to "initiate and complete review of any product containing a Schedule I substance that has successfully completed Phase 3 clinical trials ... so that rescheduling ... may proceed as quickly as practicable". My 2018...
All Major Psychedelics Produce Identical Brain Network Effects
@Nature published the most comprehensive brain scan study on psychedelics ever done. Psilocybin, LSD, ayahuasca. Different compounds. Same effect on your brain networks. Every single time.
Israel's SynBio Surge: CEOs Reveal Scaling Success
Israel has built one of the most concentrated synbio ecosystems outside the US. The country's National Bioconvergence Program, run through the Israel Innovation Authority, is specifically designed to close the gap between lab-scale innovation and commercial biomanufacturing. This session at @SynBioBeta 2026...
AACR 2026 Unveils Merck Breakthrough and Lung Cancer Hope
AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle https://t.co/u2iwCd3DKv #AACR26 $RVMD $MRK $NUVL $NUVB
Biotech Must Prioritize Collaboration, Not Nationalism, for Patients
After a week in Washington DC at one of the best new annual events by @semafor , I came to China for just 2 nights to meet some of my friends from Washington. I even had to skip this year's...
PSIL Surges as Trump Fast‑tracks Psychedelic Research
Far Out Man: The Psychedelics ETF $PSIL has destroyed its daily volume record in first 30min of trading.. Trump just signed ex order expediting research/access to psyche drugs to cure depression. The sector has been in dog house, waiting for...
Molecular Glue Daraxonrasib Shows Promise Against Pancreatic Cancer
Good summary of the marked benefit of the molecular glue drug (daraxonrasib) vs pancreatic cancer, from Revolution Medicines, and other progress (adds to the neoantigen vaccine with 6-year survival) gift link https://t.co/qk7Ar9dCAQ https://t.co/SMiA51fiwX
LLY Acquires Kelonia for $3.25bn After ASH25 Insights
It's official: $LLY buying Kelonia for $3.25bn + milestones. @ByMadeleineA take on the #ASH25 dataset that triggered this move: https://t.co/nVUNlq7YlO
Certain Drugs Like SGLT2 Inhibitors Cut Mortality Risk
A 2024 study on half a million UK individuals analyzed the mortality effects of 406 medications 92% were seen to be associated with increased mortality risk because of the underlying diseases. However, 14 were surprisingly associated with reduced mortality. An overview by...
GSK's Blenrep Approved in China for Multiple Myeloma
#GSK Blenrep (belantamab mafodotin) approved in China with a Bortezomib and Dexamethasone combo for treating Adults with a form of multiple myeloma.
AI-Driven Drug Discovery: Current Landscape and Future Promise
Cool review and perspective on the current state and the future of AI-powered drug discovery https://t.co/AgwqOlt4RU
Trump Cuts Crucial Health Research Funding, Fueling Crisis
This piece in the WaPo summarizes what I've been say. The feds under Trump are choking off research dollars -- particularly for women's health, cancer and mental health. Young researchers are particularly hard hit, steering scientists into other work. It's...
FDA Approves Breakthrough Therapy for Critically Ill Children
FDA says ‘yes’ to transformative therapy for sick children — and more media coverage of UCLA https://t.co/N6AJsRwCyX
Combined NMN and CD38 Inhibitor Rejuvenates Aging Muscles
Double-Pronged NAD Preservation: Delaying Cellular Senescence and Initiating Musculoskeletal Regeneration https://t.co/bnkkn0xblj Scheme 1: A novel synergistic drug combination (N + A) consisting of an NAD+ precursor (NMN) and an NAD+ consumption (CD38) inhibitor (API) promotes musculoskeletal regeneration in aging.
AI-Optimized Molecules Drive Clinical Interest and Expansion
#AACR2026 is in full swing and our posters are very popular. And some pharma companies realized that we have clinical data now and the molecules were AI-optimized to avoid the common liabilities. Finally, some genuine interest and we will have...
Unexpected Insight Among 11 Lessons From AACR26
11 things I learned at #AACR26 Industry Partnering event – number 7 may well surprise you: https://t.co/T0ePbaIU1K https://t.co/CMh15HfnnG
Lung‑resident Memory B Cells Drive Lasting Flu Protection
Long-term flu protection may depend on lung-resident memory B cells, whose persistence is shaped by the strength of B cell receptor signaling, offering new directions for vaccines targeting immune defenses within lung tissue. immunology
Nrf2 Activation Offers Therapeutic Promise, Yet Requires Caution
Nrf2 Activation in Inflammatory Diseases: A Review of Natural and Synthetic Modulators 🔑 Mechanistic insights and preclinical and clinical evidence on the role of Nrf2 in inflammatory diseases and evaluates the therapeutic potential of its key activators. “ The nuclear factor...
KRAS Targeting Fuels $30B Valuation for RVMD
The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades Or, how $RVMD is now worth $30B https://t.co/iFilUpezjn via @angRchen #AACR26
USC Compound Halts Alzheimer-Linked Brain Inflammation
As a medical school professor at USC, this one is personal. My colleagues at Keck School of Medicine developed a compound that stops brain inflammation linked to Alzheimer's -- while preserving normal brain function. The target: cPLA2, an enzyme that drives inflammation...
Order Set to Speed Psychedelic Drug Research Access
the order will dramatically accelerate access to new medical research and treatments based on psychedelic drugs
HHS Partners to Boost Psychedelic Trial Data, Prioritize Breakthroughs
HHS will work with the Department of Veterans Affairs, as well as the private sector, to increase clinical trial participation, data sharing, and real-world evidence generation regarding psychedelic drugs, and shall prioritize drugs that have received Breakthrough Therapy status
Chinese Biotech's Global Surge May Hinge on AI
China’s drug makers are speeding up – will AI be their secret weapon? Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level? No "overcapacity" here.... https://t.co/sktFORaVey via @scmpnews
Amgen's Potts Lab Unveils Universal Molecular Glue Platform
Next up #aacr26 is @pottslab from Amgen discussing their broad and diverse molecular glue & degrader platform “any target, every time” https://t.co/SfJ0jGYene
Funding Global Cancer Research to Cure Every Patient
EVERY CANCER. EVERY PATIENT. EVERYWHERE. @ConquerCancerFd of the American Society of Clinical Oncology (@ASCO) raises funds to support the world's leading researchers who are improving treatments & discovering cures for patients around the world. https://t.co/du6r6gdsgV #ASCO26
DepMap's Future: PRMT5 Inhibitor Differences Unveiled
Excellent talk from Bill Sellers on future directions with DepMap. Interesting differences between different PRMT5 inhibitors (SAM & MTA) and how they compare with selective inhibitors #aacr26 https://t.co/xfmKVqEpp1
Late‑stage Oral Cocktail Adds 33% Lifespan in Obese Mice
An oral drug combination, including a senolytic (quercetin), NR, urolithin A, and alpha-lipoic acid, extended median remaining lifespan in mice by 33%. Important to note, however, that the mice were fed a high-fat "Western Diet" and the intervention started at 18...
Trump EO Accelerates Psychedelic Research for PTSD and Addiction
Delighted to see the Trump EO easing research into psychedelics for PTSD, depression, and addiction. It was a prescient choice by Rick Doblin and others to explicitly research psychedelics for PTSD in veterans. Makes it so much easier to get...
Hassan Predicted Sugammad
Also, after all these years and all the FDA delays, Fred Hassan was right about sugammadex... except it took a really long time. (This is a pharma deep cut, links in the comments.)
President Signs Order to Boost PTSD Drug Research
JUST IN: The president signed an executive order to ramp up research on drugs for PTSD and other mental health issues.
First‑Dollar Coverage Boosts Affordability, Keeps R&D Incentives
Should you ever find yourself in a position to talk healthcare policy with anyone and they ask “so what are saying are the right fixes?”, NPLB put essentials in one place. Plain, short. Solve affordability w/ 1st $ coverage; preserve...
Joe Rogan's Text Spurs Federal Psychedelic Policy Shift
How a text from Joe Rogan helped remake the federal government's approach to psychedelics https://t.co/8j55tEgdx6
FDA Poised to Approve Psychedelics Amid Strong Political Push
It seems clear that the administration is poised to approved psychedelic applications at the FDA. This is strong political momentum & it seems approval is extremely likely so long as phase 3 data resemble phase 2 data. FDA Commissioner Makary: There...
Choosing Risk Over Safetyism to Save Millions
Ultimately humanity will have to decide, are we open to risk and hundreds of new therapies and cures or does safetyism win as we watch millions unnecessarily die each year (for the price of hundreds or thousands of deaths for...
Claude Opus 4.7 Autonomously Validates COVID‑19 Drug Claims
This seemed like a fun task for Claude Opus 4.7! https://t.co/Z5qJwBNYwi has an example run on the claim "Hydroxychloroquine improves clinical outcomes in patients with COVID-19." https://t.co/kn0aWevNVv describes the pipeline. I spent 3-4h on this with Claude Code managing 10...
Trump Pushes to Loosen Restrictions on Psychedelics
Clearly, he and his cabinet are already imbibing.... Trump plans to ease access to psychedelics like psilocybin, ibogaine https://t.co/pwqU0fllVb
Implantable Islet Cells May Eliminate Insulin Injections
Implantable islet cells could control diabetes without insulin injections by Anne Trafton @MIT Learn more: https://t.co/aPCxukXMW1 #MedTech #HealthTech #Tech #TechForGood https://t.co/IwjlYaJitu
China Favors Grassroots, Market-Driven Trials; US Stays Centralized
Interesting look at how China may have a more grassroots and market-oriented approach to early, experimental trials vs. the American, centralized politburo approach:
R&D Hype Unchecked: No Accountability for Drug Promises
Nice article by @TClozel in @FastCompany. Link in comments. The funny thing is that every company he mentioned and many others promised many years ago and still promise cheaper, faster, higher PoS drugs and many of them do not...
Design‑First Protein Engineering Delivers Round‑One Success
Protein engineering has a dirty secret: most of the work is in the lab, not the algorithm. You design, you test, most variants fail, you iterate for months. Scala Biodesign's bet is that the design layer can do most of that...
AI Pharma Success Measured by Speed, Cost, Not Approvals
Very often I am being asked when will the first drugs designed using AI receive regulatory approval. The answer is very simple - there are several drugs that were already approved. For example, the first antibody to receive regulatory approval...
Sex Differences Crucial for Glucagon Obesity Drug Efficacy
Male and female bodies respond differently to glucagon-based obesity drugs, and FGF21 plays an important role—especially in females. This means future treatments need to account for sex differences to be effective and safe. https://t.co/Z9gllk02Dj